Challenges in assigning endocrine-specific modes of action: Recommendations for researchers and regulators.

As regulatory programs evaluate substances for their endocrine-disrupting properties, careful study design and data interpretation are needed to distinguish between responses that are truly endocrine specific and those that are not. This is particularly important in regulatory environments where criteria are under development to identify endocrine-disrupting properties to enable hazard-based regulation. Irrespective of these processes, most jurisdictions use the World Health Organization/International Programme on Chemical Safety definition of an endocrine disruptor, requiring that a substance is demonstrated to cause a change in endocrine function that consequently leads to an adverse effect in an intact organism. Such a definition is broad, and at its most cautious might capture many general mechanisms that would not specifically denote an endocrine disruptor. In addition, endocrine responses may be adaptive in nature, designed to maintain homeostasis rather than induce an irreversible adverse effect. The likelihood of indirect effects is increased in (eco)toxicological studies that require the use of maximum tolerated concentrations or doses, which must produce some adverse effect. The misidentification of indirect effects as truly endocrine mediated has serious consequences for prompting animal- and resource-intensive testing and regulatory consequences. To minimize the risk for misidentification, an objective and transparent weight-of-evidence procedure based on biological plausibility, essentiality, and empirical evidence of key events in an adverse outcome pathway is recommended to describe the modes of action that may be involved in toxic responses in nontarget organisms. Confounding factors such as systemic toxicity, general stress, and infection can add complexity to such an evaluation and should be considered in the weight of evidence. A recommended set of questions is proffered to help guide researchers and regulators in discerning endocrine and nonendocrine responses. Although many examples provided in this study are based on ecotoxicology, the majority of the concepts and processes are applicable to both environmental and human health assessments. Integr Environ Assess Manag 2017;13:280-292. © 2016 SETAC.

[Effects of perfluorooctane sulfonate (PFOS) exposure on vitellogenin mRNA level in zebrafish (Brachydanio rerio)].

To study the endocrine disrupting effects and action mechanism of environmental levels of perfluorooctane sulfonate (PFOS) on the aquatic species, the research for the effects of PFOS exposure on vitellogenin (VTG) mRNA level in livers of zebrafish (Brachydanio rerio) was conducted. Zebrafish were exposed to PFOS at four environmental low concentrations (0.1, 1, 10, 100 microg x L(-1)) for 21 days. Livers from male and female zebrafish were collected for RNA extraction, VTG1 and VTG3 mRNA levels were measured respectively using real-time polymerase chain reaction (RT-PCR). The results show that: 1) The VTG1 and VTG3 mRNA level in the livers of male zebrafish increased after PFOS exposure. The VTG1 mRNA level increased with a positive dose response pattern, with the maximum response at 100 microg x L(-1) PFOS exposure where a significant difference compared with the control was observed. The VTG3 mRNA level increased as an inverted U-shaped dose response pattern, indicated as hormesis effects, where significant differences compared with the control were observed at 10 and 100 microg x L(-1) PFOS exposure. 2) The VTG1 mRNA level in the livers of female zebrafish increased where a significant difference compared with the control was observed at 10 microg x L(-1) PFOS exposure, but the standard errors for mRNA level at 10 and 100 microg x L(-1) PFOS exposure were distinct. The VTG3 mRNA level in the livers of female zebrafish increased at 10 microg L(-1) PFOS exposure but had no significant difference compared with the control. Thus, it deduced that PFOS exposure could be active on the endocrine system of zebrafish with the oestrogenic simulation action mechanism, and the VTG1 and VTG3 mRNA level in the livers of zebrafish might be sensitive biomarkers for the endocrine disrupting effects evaluation after PFOS exposure, with different responding patterns related to the gene subtypes and sex.

Retrospective analysis of relative parameter sensitivity in multi-generation reproductive toxicity studies.

Current suggestions towards amending the OECD two-generation protocol include omission of the second generation and inclusion of additional parameters. This study analysed the relative parameter sensitivity in 18 individually published multi-generation studies with substances toxic to fertility. Among parameters that most often determined the reproductive LOAEL were weight of testis, dam and pup as well as litter size. Several other parameters were found to be unaffected in all studies evaluated. Some substances affected a specific set of parameters, indicating that rarely affected parameters may prove crucial in individual situations. This argues for the inclusion of a wide spectrum of parameters to cover all possible effects. Less sensitive parameters, mechanistically related to more sensitive ones, may be omitted as they will unlikely contribute to the overall LOAEL. This study gives first insights and needs follow-up by more extensive analyses before firm conclusions on the design of the two-generation study protocol can be drawn.

Dose-dependent effects of phytoestrogens on bone.

Phytoestrogens have the potential to maintain bone health and delay or prevent osteoporosis. This review focuses on their dose-dependent effects on bone and their possible mechanisms of action. Phytoestrogens exert biphasic dose-dependent effects on osteoblasts and osteoprogenitor cells, stimulating osteogenesis at low concentrations and inhibiting osteogenesis at high concentrations. They inhibit osteoclast formation and activity. Recent data show that the balance between estrogen receptors and peroxisome proliferator-activated receptors, which are dose-dependently activated by phytoestrogens, determines their biological effects on bone. This review provides a new understanding of the mechanism of action of phytoestrogens and could be important for future studies to find precise beneficial doses in vivo and in clinical trials.

Sixteen hours of fasting differentially affects hepatic and muscle insulin sensitivity in mice.

Fasting readily induces hepatic steatosis. Hepatic steatosis is associated with hepatic insulin resistance. The purpose of the present study was to document the effects of 16 h of fasting in wild-type mice on insulin sensitivity in liver and skeletal muscle in relation to 1) tissue accumulation of triglycerides (TGs) and 2) changes in mRNA expression of metabolically relevant genes. Sixteen hours of fasting did not show an effect on hepatic insulin sensitivity in terms of glucose production in the presence of increased hepatic TG content. In muscle, however, fasting resulted in increased insulin sensitivity, with increased muscle glucose uptake without changes in muscle TG content. In liver, fasting resulted in increased mRNA expression of genes promoting gluconeogenesis and TG synthesis but in decreased mRNA expression of genes involved in glycogenolysis and fatty acid synthesis. In muscle, increased mRNA expression of genes promoting glucose uptake, as well as lipogenesis and beta-oxidation, was found. In conclusion, 16 h of fasting does not induce hepatic insulin resistance, although it causes liver steatosis, whereas muscle insulin sensitivity increases without changes in muscle TG content. Therefore, fasting induces differential changes in tissue-specific insulin sensitivity, and liver and muscle TG contents are unlikely to be involved in these changes.

Differential effects of PD98059 and U0126 on osteogenesis and adipogenesis.

PD98059 and U0126 are considered as specific inhibitors of the p42/44 mitogen-activated protein kinases (MAPK) pathway, which affects osteogenesis and adipogenesis. Here, we show unexpected differential effects of PD98059 and U0126 on osteogenesis and adipogenesis as well as on estrogen (E2)-induced actions in osteoprogenitor KS483 cells. PD98059 dose-dependently inhibited osteogenesis indicated by cellular alkaline phosphatase (ALP) activity and nodule formation, but stimulated adipogenesis shown by the number of adipocytes. In contrast, U0126 slightly decreased osteogenesis but had no effects on adipogenesis, although it inhibited p42/44 MAPK more potently than PD98059. Furthermore, PD98059, but not U0126, counteracted E2-induced osteogenesis and adipogenesis. Transfection experiments showed that PD98059, but not U0126, had estrogenic transcriptional activity. Interestingly, both PD98059 and U0126 potentiated E2-induced estrogenic transcriptional activity in KS483 cells, which is opposite to the response in MCF7 breast cancer cells. Our data indicate that the cross-talk between growth factors and estrogen receptor (ER)-mediated pathways in KS483 cells is different from that in MCF7 cells. In summary, the differential effects of PD98059 and U0126 indicate their actions are not exclusively due to an inhibition of MAPK pathway. Caution should be taken in the interpretation of the results obtained using these inhibitors.

Peroxisome proliferator-activated receptor gamma (PPARgamma ) as a molecular target for the soy phytoestrogen genistein.

The principal soy phytoestrogen genistein has an array of biological actions. It binds to estrogen receptor (ER) alpha and beta and has ER-mediated estrogenic effects. In addition, it has antiestrogenic effects as well as non-ER-mediated effects such as inhibition of tyrosine kinase. Because of its complex biological actions, the molecular mechanisms of action of genistein are poorly understood. Here we show that genistein dose-dependently increases estrogenic transcriptional activity in mesenchymal progenitor cells, but its biological effects on osteogenesis and adipogenesis are different. At low concentrations (< or =1 microm), genistein acts as estrogen, stimulating osteogenesis and inhibiting adipogenesis. At high concentrations (>1 microm), however, genistein acts as a ligand of PPARgamma, leading to up-regulation of adipogenesis and down-regulation of osteogenesis. Transfection experiments show that activation of PPARgamma by genistein at the micromolar concentrations down-regulates its estrogenic transcriptional activity, while activation of ERalpha or ERbeta by genistein down-regulates PPARgamma transcriptional activity. Genistein concurrently activates two different transcriptional factors, ERs and PPARgamma, which have opposite effects on osteogenesis or adipogenesis. As a result, the balance between activated ERs and PPARgamma determines the biological effects of genistein on osteogenesis and adipogenesis. Our findings may explain distinct effects of genistein in different tissues.